MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Innoviva Inc

Gesloten

SectorGezondheidszorg

17.34 0.87

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.95

Max

17.41

Belangrijke statistieken

By Trading Economics

Inkomsten

110M

64M

Verkoop

12M

100M

K/W

Sectorgemiddelde

30.561

35.739

Winstmarge

63.508

Werknemers

127

EBITDA

111M

84M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+106.98% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-69M

1.1B

Vorige openingsprijs

16.47

Vorige sluitingsprijs

17.34

Nieuwssentiment

By Acuity

46%

54%

179 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Innoviva Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2025, 16:58 UTC

Winsten

BMW Trims 2025 View, Citing Weaker Performance in China

7 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 okt 2025, 23:19 UTC

Marktinformatie

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 okt 2025, 22:40 UTC

Marktinformatie

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 20:44 UTC

Populaire aandelen

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 okt 2025, 19:42 UTC

Marktinformatie

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 okt 2025, 19:23 UTC

Acquisities, Fusies, Overnames

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 okt 2025, 19:07 UTC

Marktinformatie

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 okt 2025, 15:33 UTC

Marktinformatie

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 okt 2025, 15:25 UTC

Marktinformatie

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 okt 2025, 15:15 UTC

Marktinformatie

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 okt 2025, 15:04 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 okt 2025, 15:04 UTC

Marktinformatie

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 okt 2025, 14:52 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Innoviva Inc Prognose

Koersdoel

By TipRanks

106.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.6 USD  106.98%

Hoogste 55 USD

Laagste 17 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Innoviva Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

4

Buy

0

Hold

1

Sell

Technische score

By Trading Central

18.57 / 18.75Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

179 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat